Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos, sex toys and adult toys.
Popular Articles

Rates Of Severe Childhood Obesity Have Tripled
Rates of severe childhood obesity have tripled in the last 25 years, putting many children at risk for diabetes and heart disease, according to a report in Academic Pediatrics by an obesity expert at Brenner Children"s Hospital, part of Wake Forest University Baptist Medical Center.
buy viagra
North Carolina Senate Delays Vote On Latest Version Of Sex Education Bill
The North Carolina Senate has delayed until Wednesday its vote on a bill (S. 221) that would require public school systems in the state to offer a sex education curriculum that includes information on both abstinence and prevention of pregnancy and sexually transmitted infections, the Fayetteville Observer reports. Currently, most public schools in the state teach abstinence-only sex education (Fayetteville Observer, 6/11).The bill, which a state Senate committee approved earlier in the week, made major changes to a state House version (H.B. 88) that conservative and liberals in the chamber approved as a compromise measure. The House bill would have required parents to choose from three sex education options: abstinence-only; an abstinence-based program with information on pregnancy and STI prevention; or no sex education. The third option would be the default if parents did not make a selection (Woolverton, Fayetteville Observer, 6/11).The Senate version of the bill was designed to merge the abstinence-only and the abstinence-based comprehensive options of the House bill. Parents would be able to request that their children not receive the comprehensive portions of the lessons.According to the Observer, some lawmakers objected to the idea in the House bill that students would receive no sex education if their parents failed to make a selection. In addition, some school officials voiced concern that the House version would require more teachers and classroom space to meet the requirements for three separate options (Fayetteville Observer, 6/11).
plan for health
News of the day
Blood Flow In Alzheimer's Disease
Dr. Jennifer C Palmer and colleagues at the University of Bristol have discovered that endothelin converting enzyme-2 (ECE-2) may cause the decrease in cerebral blood flow seen in Alzheimer"s disease. These results are presented in the July 2009 issue of the American Journal of Pathology.
Diagnostics

Stem Cell Therapeutics Receives Clearance From Health Canada To Proceed With The Phase IIb Clinical Stroke Trial

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)("SCT" or "the Company") has received a No Objection Letter ("NOL") from Health Canada for the modified REGENESIS protocol using NTx®-265 for a Phase IIb clinical trial treating acute ischemic stroke. Dr. Alan Moore, President and CEO, commented as follows: "We are pleased that Health Canada has issued an NOL for the modified REGENESIS clinical trial. This welcome development means that we are able to proceed with recruitment of patients, testing the NTx®-265 regimen in patients with acute ischemic stroke in Canada again and demonstrating the ability of this novel approach to speed recovery from stroke disabilities. This satisfying development can be directly attributed to the perseverance and strong belief of all the SCT staff that NTx®-265 will, in the future, redefine the therapies available to patients recovering from acute ischemic stroke, traumatic brain injury, and neurological disease." About REGENESIS (a Phase II prospective, randomized, double-blind, placebo controlled study of NTx®-265: hCG and epoetin alfa in acute ischemic stroke patients): NTx®-265 is SCT"s lead therapeutic regimen of two approved and clinically well-defined drugs, human Chorionic Gonadotropin ("hCG") and Erythropoietin ("EPO"), targeting the treatment of stroke. The twin objectives of the treatment are to stimulate the growth and differentiation of new neurons to replace the brain cells that were lost or damaged by the stroke, and importantly, to direct motor, visual, and cognitive recovery after the acute ischemic stroke. Encouraging clinical results from SCT"s BETAS Phase IIa stroke trial were presented at the International Stroke Conference in February 2009, showing clinically relevant recovery in 12 of 12 patients who received the complete treatment. SCT received clearance from the FDA to proceed with the Phase IIb stroke trial on May 15, 2009. Stem Cell Therapeutics Corp.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009